与标准瓶子和囊相比,许可准备使用的静脉注射产品的经济证据:系统审查
Suzanne Al-Rawi1, Matthew Greening1, Sue Ladds1
1Infusions and Special Medicine Programme, NHS England, London, UK.
Anaesthesia
|January 15, 2026
概括
准备注射的注射药物可以减少医院的错误,浪费和准备时间. 虽然显示出经济效益,但由于研究的局限性,需要更多针对英国的具体研究.
科学领域:
- 药物经济学 药物经济学
- 医疗保健服务研究 医疗服务研究
- 药物安全 药物安全
背景情况:
- 注射药物占英格兰NHS支出的很大一部分 (每年70亿英).
- 经许可的准备使用 (RTA) 产品通过消除准备步骤来提高效率和安全性.
- 大多数NHS医院仍然喜欢传统的瓶子,因为前期成本较低.
研究的目的:
- 评估RTA静脉注射药物在医院环境中的临床和经济影响.
- 综合有关RTA产品成本,浪费,准备时间和药物错误的证据.
主要方法:
- 对16项评估RTA静脉注射药物的研究进行系统审查.
- 包括来自NHS和英国政府来源的灰色文献.
- 分析重点是成本,浪费,准备时间和药物错误.
主要成果:
- 一般来说,RTA产品减少了准备错误,药物浪费和准备时间.
- 减少药物不良事件和工作流中断的证据主要来自观察性研究.
- 经济评估表明了潜在的节约,但具体取决于背景和假设.
结论:
- RTA产品与更少的准备错误,更短的准备时间和更少的药物浪费有关,具有潜在的经济优势.
- 这些发现的确定性受到研究异质性,非随机设计和特定环境成本的限制.
- 需要更多具有标准化结果的多中心研究,特别是针对英国的具体证据.
相关概念视频
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
178
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
178
Drug Product Performance: In Vitro–In Vivo Correlation
229
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
229
Routes of Drug Administration: Parenteral
2.8K
The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
2.8K
One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance
345
Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
345
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
251
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
251
Bioequivalence: Overview
1.8K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.8K


